References
1. Portman D.J., Gass M.L. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and the North American Menopause Society. Menopause. 2014; 21 (10): 1063-8.
2. Smetnik V.P., Yureneva S.V., Ermakova E.I., Glazunova A.V. Genito-urinar menopausal syndrome. Clinical Protocol. Klimakteriy [Menopause]. 2015; 1: 2-23. (in Russian)
3. Yureneva S.V., Ermakova E.I., Glazunova A.V. Genitourinary syndrome of menopause in peri- and postmenopausal patients: Diagnosis and therapy (short clinical guideline). Akusherstvo i ginekologiya [Obstetrics and Gynecology]. 2016; 5: 138-44. (in Russian)
4. The North American Menopause Society. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause. 2013; 20 (9): 888-902.
5. Cardozo L., Staskin D. Textbook of Female Urology and Urogynaecology. London, 2005: 183-227.
6. Griebling T.L., Liao Z., Smith P.G. Systemic and topical hormone therapies reduce vaginal innervation density in postmenopausal women. Menopause. 2012; 19: 630-5.
7. Frank S.M., Ziegler C., Kokot-Kierepa M., Maamari R., Nappi R.E. Vaginal Health: Insights, Views & Attitudes (VIVA) survey - Canadian cohort. Menopause Int. 2013; 19 (1): 20-7.
8. Smetnik V.P. Estrogens. Moscow: Prakticheskaya meditsina, 2012: 128-33. (in Russian)
9. Eprikyan E.G., Yureneva S.V., Ermakova E.I., Glazunova A.V. Genitourinary syndrome of menopause: optimization of therapy for vaginal symptoms Ginekologiya [Gynecology]. 2018; 20 (3): 52-6. (in Russian)
10. Pinkerton J.V.Pinkerton J.V. Hormone Therapy: Key Points From NAMS 2017 Position Statement. Clin Obstet Gynecol. 2018; 61 (3): 44753. DOI: 10.1097/GRF.0000000000000383
11. Kagan R., Kellogg-Spadt S., Parish S.J. Practical Treatment Considerations in the Management of Genitourinary Syndrome of Menopause. Drugs Aging. 2019; 36 (10): 897-908. DOI: 10.1007/s40266-019-00700-w
12. Kaprin A.D., Starinsky V.V., Petrova G.V. Malignant neoplasms in Russia in 2018. Moscow, 2019: 5-30. (in Russian)
13. Santoro N., Komi J. Prevalence and impact of vaginal symptoms among postmenopausal women. J Sex Med. 2009; 6 (8): 2133-42.
14. Cella D., Fallowfield L.J. Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy. Breast Cancer Res Treat. 2008; 107 (2): 167-80.
15. Carter J., Goldfrank D., Schover L.R. Simple strategies for vaginal health promotion in cancer survivors. J Sex Med. 2011; 8 (2): 549-59.
16. Loprinzi C.L., Wolf S.L., Barton D.L., Laack N.N. Symptom management in premenopausal patients with breast cancer. Lancet Oncol. 2008; 9 (10): 993-1001.
17. Biglia N., Peano E., Sgandurra P., Moggio G., Panuccio E., Migliardi M., et al. Low-dose vaginal estrogens or vaginal moisturizer in breast cancer survivors with urogenital atrophy: a preliminary study. Gynecol Endocrinol. 2010; 26 (6): 404-12.
18. Reesa M., Angioli R., Colemanc R.L., Glasspoold R., Plotti F., Simoncini T., et al. Официальное заявление Европейского общества по менопаузе и андропаузе (EMAS) и Международного общества по гинекологическому раку (IGCS) о коррекции симптомов менопаузы и профилактике и лечении остеопороза после гинекологического рака. Maturitas. 2020; 134: 56-61.
19. Faubion S.S., Larkin L.C., Stuenkel C.A., Bachmann G.A., Chism L.A., Kagan R., et al. Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: consensus recommendations from The North American Menopause Society and The International Society for the Study of Women's Sexual Health. Menopause. 2018; 25 (6): 596608. DOI: 10.1097/GME.0000000000001121
20. Baber R.J., Panay N., Fenton A.; and the IMS Writing Group. 2016 IMS Recommendations on women's midlife health and menopause hormone therapy. Climacteric. 2016; 19 (2): 109-50.
21. Tersigni C., Di Simone N., Tempestilli E., Cianfrini F., Russo R., Moruzzi M.C., et al. Non-hormonal treatment of vulvo-vaginal atrophy-related symptoms in post-menopausal women. J Obstet Gynaecol. 2015; 35 (8): 835-8.
22. Stute P., May T.W., Masur C., Schmidts-Winkler I.M. Efficacy and safety of non-hormonal remedies for vaginal dryness: open, prospective, randomized trial. Climacteric. 2015; 18 (4): 582-9.
23. Jokar A., Davari T., Asadi N., Ahmadi F., Foruhari S. Comparison of the hyaluronic acid vaginal cream and conjugated estrogen used in treatment of vaginal atrophy of menopause women: a randomized controlled clinical trial. Int J Community Based Nurs Midwifery. 2016; 4 (1): 69-78.
24. Dobrokhotova Yu.E., Ilyina I.Yu., Venediktova M.G., Morozova K.V., Suvorova V.A. Local nonhormonal therapy in patients with genitourinary menopausal syndrome. Rossiyskiy vestnik akushera-ginekologa [Russian Bulletin of Obstetrician-Gynecologist]. 2018; 3: 88-93. (in Russian)
25. Chernova N.I., Arutyunyan E. Current aspects of treatment in patients with dystrophy and atrophy of the intimate area. What is new? Rossiyskiy vestnik akushera-ginekologa [Russian Bulletin of Obstetrician-Gynecologist]. 2018; 3: 95-8. (in Russian)